Scribe Therapeutics posts Q2 2026 $1.9M collaboration revenue, $6.5M net loss
Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9 million and a net loss of $6.5 million, or $2.62 per basic and diluted share. Cash, cash equivalents and marketable securities were $43.0 million as of June 30, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.